NEW YORK (GenomeWeb) – VolitionRx announced today that it received CE marking for its blood-based NuQ Colorectal Cancer Screening Triage Test, clearing it for commercialization in the European Union.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.